Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19565507 | 1.00 | NISCH (0.44) | NISCHLTA4HCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL12610431 | 1.00 | NISCH (0.44) | NISCHLTA4HCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL10938593 | 0.83 | SMN1; SMN2 (0.55) | LTA4HHTT | |
| SCHEMBL23646850 | 0.83 | SMN1; SMN2 (0.55) | LTA4HHTT | |
| SCHEMBL1628134 | 0.83 | SMN1; SMN2 (0.55) | LTA4HHTT | |
| SCHEMBL406079 | 0.82 | POLB (0.47) | POLB | |
| SCHEMBL18469502 | 0.81 | ITGB2 (0.46) | LTA4HCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18469558 | 0.78 | ITGB2 (0.43) | LTA4HCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL19393069 | 0.78 | CA2 (0.46) | — | |
| SCHEMBL5274470 | 0.77 | NISCH (0.46) | NISCHLTA4HPOLBMTNR1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20220213126-A1 | SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | JOHN WAYNE CANCER INSTITUTE (US) | 2022-07-07 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070099875-A1 | Aspartyl protease inhibitors | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070072852-A1 | 2-(Imino-),3,6-(dimethyl-),4-(oxo=),6-(3-(methoxy-)phenyl)-(1,4-phenylene)-perhydropyrimidine; aspartyl protease inhibitors; cardiovascular diseases; cognition activators; neurodegenerative diseases; viricides; HIV; enzyme inhibitors of plasmepins, cathepsin D and protozoal enzymes; hypotensive agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| EP-0429535-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-05 | — | — | EP | disclosed |
| EP-0359400-A1 | Fungicidal benzodioxane amine derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| WO-1990002122-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | STS, GABRB2, SULT2A1 | NISCH 1811/4885LTA4H 1141/4885CHRNB4 1217/4885 |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | SDHA, SQOR, SDHB | NISCH 616/4885LTA4H 2943/4885CHRNB4 636/4885 |
| US-20220213126-A1 | SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | TFEB, SQSTM1, BECN1 | NISCH 3569/4885LTA4H 4472/4885CHRNB4 2376/4885 |
| US-20070072852-A1 | 2-(Imino-),3,6-(dimethyl-),4-(oxo=),6-(3-(methoxy-)phenyl)-(1,4-phenylene)-perhydropyrimidine; aspartyl protease inhibitors; cardiovascular diseases; cognition activators; neurodegenerative diseases; viricides; HIV; enzyme inhibitors of plasmepins, cathepsin D and protozoal enzymes; hypotensive agents | CTSD, PRSS1, CTSZ | NISCH 2747/4885LTA4H 2674/4885CHRNB4 3574/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NISCH 3172/4885LTA4H 3506/4885CHRNB4 4688/4885 |
| US-20060281729-A1 | Macrocyclic heterocyclic aspartyl protease inhibitors | CHRM1, CHRM2, CHRM5 | NISCH 4205/4885LTA4H 548/4885CHRNB4 260/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | NISCH 459/4885LTA4H 337/4885CHRNB4 4842/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | NISCH 3172/4885LTA4H 3506/4885CHRNB4 4688/4885 |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | GABBR1, GABBR2, SQOR | NISCH 349/4885LTA4H 3232/4885CHRNB4 495/4885 |
| US-20070099875-A1 | Aspartyl protease inhibitors | PRSS1, PRSS3, TMPRSS11D | NISCH 3754/4885LTA4H 968/4885CHRNB4 764/4885 |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | MYC, MYCBP, MAX | NISCH 2522/4885LTA4H 4725/4885CHRNB4 2552/4885 |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | GPR119, LIPC, GLP1R | NISCH 647/4885LTA4H 1575/4885CHRNB4 4707/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | NISCH 3172/4885LTA4H 3506/4885CHRNB4 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.